Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age50+
SponsorHospital Authority, Hong Kong
About this trial
We aimed to investigate the success rate of a planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab, for nAMD to achieve stability without recurrence at a tertiary eye centre.
Eligibility criteria
Qualifiers
None
Disqualifiers
eyes that received any anti-VEGF therapy in the prior six months,
eyes with other disease entities (e.g., diabetic macula oedema, retinal vein occlusions, central serous chorioretinopathy, myopicmacular neovascularisation),
concurrent macula laser (except photodynamic therapy) and ocular surgery (e.g., cataract surgery or vitrectomy) in the prior six months and the study period.
Trial design
Treatments tested in this trial
- Faricimab Injection [Vabysmo]
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov